Synapse - Diane Reidy

Results (48)

Early-onset pancreatic neuroendocrine tumors: Clinical presentation, pathology features, and oncological outcomes

Journal Article

Pulvirenti, A.; Hauser, H. F.; Fiedler, L. M.; McIntyre, C. A.; Le, T.; Reidy-Lagunes, D. L.; Soares, K. C.; Balachandran, V. P.; Kingham, T. P.; D'Angelica, M. I.; more...
Annals of Surgery (2024)

Fulltext@MSK | Save

Recurring pancreatic neuroendocrine tumor: Timing and pattern of recurrence and current treatment

Journal Article

Pulvirenti, A.; Javed, A. A.; Michelakos, T.; Sekigami, Y.; Zheng, J.; Kalvin, H. L.; McIntyre, C. A.; Nebbia, M.; Chou, J. F.; Gonen, M.; more...
Annals of Surgery (2023)

Fulltext@MSK | Save

Early onset well-differentiated pancreatic neuroendocrine tumors: clinical presentation, pathologic features, and oncological outcomes

Meeting Abstract

Pulvirenti, A.; Hauser, H.; Le, T.; McIntyre, C.; Reidy-Lagunes, D.; Wei, A.; Raj, N.
Pancreas (2022)

Fulltext@MSK | Save

Treatment response and clinical outcomes of neuroendocrine neoplasms (NENs) treated with immune checkpoint inhibitors (ICIs): A single institution experience

Meeting Abstract

Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy-Lagunes, D.; Raj, N.
Pancreas (2022)

Fulltext@MSK | Save

Phase 2 trial of pembrolizumab-based therapy in previously treated extrapulmonary poorly-differentiated neuroendocrine carcinomas: Results of part B (pembrolizumab plus chemotherapy)

Meeting Abstract

Chan, J. A.; Raj, N. P.; Aggarwal, R. R.; Hope, T. A.; Kolli, K. P.; Zhang, L.; Fattah, D.; Calabrese, S.; Grabowsky, J. A.; Perez, K.; more...
Pancreas (2022)

Fulltext@MSK | Save

Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well- differentiated neuroendocrine tumors (WDNETs)

Meeting Abstract

Raj, N.; Cruz, E.; Chou, J.; Capanu, M.; DeMore, A.; Hauser, H.; Heffernan, O.; Le, T.; Saltz, L.; Reidy-Lagunes, D.
Pancreas (2022)

Fulltext@MSK | Save

Treatment response and clinical outcomes of well-differentiated (WD) high-grade (HG) neuroendocrine tumors (NETs) to (177)Lu-DOTATATE

Meeting Abstract

Coffman, K.; Bodei, L.; Le, T.; Choi, Y.; Chou, J.; Capanu, M.; Dunphy, M.; Fox, J.; Grewal, R.; Reddy, R.; more...
Pancreas (2022)

Fulltext@MSK | Save

Blood-based genomic assessment of clinical efficacy and toxicity of (177)Lu-DOTATATE of neuroendocrine tumors

Meeting Abstract

Bodei, L.; Raj, N.; Do, K. G.; Krebs, S.; Reidy-Lagunes, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schöder, H.
Pancreas (2022)

Fulltext@MSK | Save

Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results From the phase 3 SPINET study